PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9704459

Complement regulation.

S Meri·H Jarva
View original source ↗Export metadata ↓

Abstract

Because of its strong potential for generating inflammation and causing tissue destruction the complement system has to be kept strictly under control. Cells of the host need special protection against the cytolytic complement system. This paper will describe how inappropriate activation of complement in the fluid phase is prevented and how viable human blood cells defend themselves against being destroyed and cleared away by the complement system. Since disturbances in complement regulation occasionally result in disease a brief reference will be made to two of the syndromes caused by complement regulator deficiency, hereditary angioedema (HAE) and paroxysmal nocturnal hemoglobinuria (PNH).

Explore related subjects

AngioedemaAnimalsAntigens, CDCD55 AntigensCarrier ProteinsClusterinCollectinsComplement ActivationComplement C1 Inactivator ProteinsComplement Factor HComplement Inactivator ProteinsComplement System ProteinsEnzyme ActivationFeedbackGenes, DominantGlomerulonephritis, MembranoproliferativeGlycoproteinsHemoglobinuria, ParoxysmalHumansIon ChannelsMembrane Cofactor ProteinMembrane GlycoproteinsModels, BiologicalMolecular ChaperonesOpsonin ProteinsReceptors, ComplementSwineSwine DiseasesVitronectinJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Meri, H Jarva. 1998. Complement regulation.. https://doi.org/10.1111/j.1423-0410.1998.tb05434.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

[Aspirin: allergy or intolerance].

PURPOSE: The paper describes the clinical characteristics of patients with aspirin-induced asthma and/or urticaria, angioedema, shock, the results of the challenge tests and the evolution of this disease. MAIN POINT: The authors present the different arguments supporting the physiopathological mechanisms from genetics to the inhibition of cyclooxugenase or the leukotriene hypothesis. PROSPECTIVES: Finally, they recall the methodology to be used for a good clinical practice on this controversial field of research.

Angioedema↗
PubMed2000

Sensitization to gelatin in children with systemic non-immediate-type reactions to varicella vaccines.

BACKGROUND: We recently found that four children who experienced systemic immediate-type reactions to varicella vaccine with gelatin had anti-gelatin IgE. We also found systemic non-immediate-type allergic reactions, which mainly consist of systemic cutaneous signs, appearing several hours or more after the vaccination. OBJECTIVE: To investigate the relationship between immune responses to gelatin and non-immediate-type reactions to gelatin-containing varicella vaccines, we measured anti-gelatin IgE and IgG in the sera of the children with these allergic reactions. METHODS: Serum samples were taken from 21 children who showed non-immediate-type reactions to varicella vaccines. As a positive control, serum samples were taken from 33 children who showed immediate-type reactions to varicella vaccine and had anti-gelatin IgE. As a negative control, serum samples were taken from 50 children who showed no reaction to the vaccine. We then examined anti-gelatin IgE and IgG in sera of the children. RESULTS: Of 21 children with non-immediate-type reactions, two (10%) had anti-gelatin IgE and six (29%) had anti-gelatin IgG. In the positive control group, all 33 children with immediate-type reactions had anti-gelatin IgG as well as IgE. In the negative control group, all 50 children who showed no allergic reaction to varicella vaccines had neither anti-gelatin IgE nor IgG. CONCLUSIONS: These results suggest that the possibility exists that some non-immediate-type reactions to varicella vaccine are caused by immune reactions to gelatin.

Angioedema↗